丁-2-炔-1,4-二醇乙酸酯 | 83466-88-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 丁-2-炔-1,4-二醇乙酸酯
• 英文名称: 2-Butyne-1,4-diol, monoacetate
• 英文别名: acetic acid;but-2-yne-1,4-diol
• CAS: 83466-88-0
• 化学式: C6H10O4
• 分子量: 146.14
• InChiKey: QHSZIJSZJPYJMP-UHFFFAOYSA-N

物化性质

• 沸点：
  131-132 °C(Press: 12 Torr)
• 密度：
  1.145±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.93
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  77.8
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• [EN] 2-(1H-INDAZOL-6-YLAMINO)-BENZAMIDE COMPOUNDS AS PROTEIN KINASES INHIBITORS USEFUL FOR THE TREATMENT OF OPHTALMIC DISEASES<br/>[FR] COMPOSES DE 2-(1H-INDAZOL-6-YLAMINO)-BENZAMIDES EN TANT QU'INHIBITEURS DE PROTEINES KINASES UTILES POUR LE TRAITEMENT DE MALADIES OPHTALMIQUES
  申请人：PFIZER

  公开号：WO2004056806A1

  公开（公告）日：2004-07-08

  Indazole compounds that modulate and/or inhibit the ophthalmic diseases and the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating ophthalmic diseases and cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma,rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

  描述了可以调节和/或抑制眼科疾病和某些蛋白激酶活性的吲哚唑化合物。这些化合物和含有它们的药物组合物能够介导酪氨酸激酶信号传导，从而调节和/或抑制不需要的细胞增殖。该发明还涉及含有这些化合物的药物组合物的治疗或预防用途，以及通过给予这些化合物的有效剂量来治疗眼科疾病和癌症以及与不需要的血管生成和/或细胞增殖相关的其他疾病状态，如糖尿病视网膜病变、新生血管性青光眼、类风湿性关节炎和牛皮癣。
• NONAQUEOUS ELECTROLYTE SOLUTION FOR LITHIUM BATTERY, LITHIUM BATTERY USING SAME, AND FORMYLOXY GROUP-CONTAINING COMPOUND USED THEREIN
  申请人：Abe Koji

  公开号：US20110183199A1

  公开（公告）日：2011-07-28

  Disclosed are a nonaqueous electrolytic solution for lithium secondary battery comprising an electrolyte dissolved in a nonaqueous solvent and containing at least one compound represented by the formula (I) in an amount of from 0.01 to 10% by mass of the nonaqueous electrolytic solution; a lithium battery containing the electrolytic solution and excellent in low-temperature and high-temperature cycle property; and a formyloxy group-containing compound having a specific structure which is used in lithium batteries, etc. (wherein X represents an alkylene group, an alkenylene group or an alkynylene group; R 1 represents H, an alkyl group, a cycloalkyl group or a group of the formula (II); R 2 represents an alkyl group, a cycloalkyl group or a group of the formula (II); R 3 to R 7 each represent H, F, a methoxy group or an ethoxy group.)

  本发明揭示了一种用于锂二次电池的非水电解质溶液，其中包含在非水溶剂中溶解的电解质，并且含有至少一种化合物，该化合物由公式（I）表示，并占非水电解质溶液的质量的0.01％至10％; 一种锂电池，其中包含该电解质溶液，并具有低温和高温循环性能优异的特点;以及一种具有特定结构的甲氧基羰基基团的化合物，该化合物用于锂电池等中。（其中X代表烷基，烯基或炔基；R1代表H，烷基，环烷基或公式（II）的基团；R2代表烷基，环烷基或公式（II）的基团；R3至R7每个代表H，F，甲氧基或乙氧基。）
• Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
  申请人：Agouron Pharmaceuticals, Inc.

  公开号：US20040192735A1

  公开（公告）日：2004-09-30

  Indazole compounds that modulate and/or inhibit the ophthalmic diseases and the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating ophthalmic diseases and cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

  本文描述了调节和/或抑制眼科疾病和某些蛋白激酶活性的吲唑化合物。这些化合物和含有它们的药物组合物能够介导酪氨酸激酶信号传导，从而调节和/或抑制不必要的细胞增殖。本发明还涉及含有这些化合物的药物组合物的治疗或预防用途，以及通过给予这些化合物的有效量来治疗眼科疾病和与不必要的血管生成和/或细胞增殖相关的癌症和其他疾病状态，如糖尿病视网膜病变、新生血管性青光眼、类风湿性关节炎和银屑病。
• A RUTHENIUM-BASED CATALYST COMPOSITION FOR OLEFIN METATHESIS
  申请人：BP Corporation North America Inc.

  公开号：EP0841988B1

  公开（公告）日：2002-06-19
• A RUTHENIUM-BASED CATALYST SYSTEM FOR OLEFIN METATHESIS
  申请人：AMOCO CORPORATION

  公开号：EP0841988A1

  公开（公告）日：1998-05-20